Open AccessA novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer
Author(s) -
Hongcao Lin,
Chonghui Hu,
Shusen Zheng,
Xiang Zhang,
Rufu Chen,
Quanbo Zhou
Publication year - 2021
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.202922
Subject(s) - pancreatic cancer , oncology , medicine , nomogram , erlotinib , gene signature , cancer , epidermal growth factor receptor , chemotherapy , gene , gene expression , biology , biochemistry
Pancreatic cancer is a lethal disease. Chemoresistance is one of the characteristics of pancreatic cancer and leads to a poor prognosis. This study built an effective predictive model for personalized treatment and explored the molecular mechanism of chemoresistance. A four-gene signature, including serine peptidase inhibitor Kazal type 1 ( SPINK1 ), anoctamin 1 ( ANO1 ), desmoglein 3 ( DSG3 ) and GTPase, IMAP family member 1 ( GIMAP1 ) was identified and associated with prognosis and chemoresistance in the training group. An internal testing dataset and the external dataset, GSE57495, were used for validation and showed a good performance of the gene signature. The high-risk group was enriched with multiple oncological pathways related to immunosuppression and was correlated with epidermal growth factor receptor (EGFR) expression, a target molecule of Erlotinib. In conclusion, this study identified a four-gene signature and established two nomograms for predicting prognosis and chemotherapy responses in patients with pancreatic cancer. The clinical value of the nomogram was evaluated by decision curve analysis (DCA). It showed that these may be helpful for clinical treatment decision-making and the discovery of the potential molecular mechanism and therapy targets for pancreatic cancer.